UCB and Amgen announce positive results from Phase III romosozumab study on men with osteoporosis

Belgian biopharmaceutical company UCB (Euronext Brussels: UCB) and US biotech firm Amgen (Nasdaq: AMGN) have announced positive top-line results in a pivotal Phase III trial of romosozumab for the treatment of osteoporosis.

The study met its primary endpoint by showing a significant increase in bone mineral density (BMD) at the lumbar spine in men with the condition who were treated with romosozumab compared to placebo, over a 12-month period.

Dr Iris Loew-Friedrich, chief medical officer of UCB, said: “Although there has been considerable progress in the treatment and management of osteoporosis, a large unmet medical need remains. One in three women and one in five men over the age of 50 will experience an osteoporosis-related fracture in their lives. These positive results add to our growing body of Phase III data demonstrating romosozumab’s potential to build bone strength and to decrease fracture risk and thus help fill an unmet need for patients with osteoporosis.”